Most of us have never heard of it, but nonalcoholic steatohepatitis is a chronic disease that threatens the lives of around 30 million people in the U.S. alone. There aren't any available treatments for NASH, and it looks like Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) could generate billions for its shareholders with a drug that's several steps ahead of the competition.Does Intercept's lead over a tsunami of competitors make the stock a buy now?